OPKO HEALTH, INC. (OPK) earnings date
Feb 25, 2027, after close estimated
Estimated from the company's SEC filing cadence. The company has not confirmed it. Companies usually announce two to four weeks ahead.
- Fiscal period
- Q4 FY2026
- Confidence
- 52% chance of landing within a day
- Source
- Filing history on EDGAR
- Last checked
- 2026-11-19
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
How this company behaves
| Announces its report date | Not enough announcements on file yet to say |
| Reports after the quarter ends | 30 days, typically, give or take 13 (last 8 releases) |
Last 8 releases
| Period | Released | Timing | Days after period end | Filing |
|---|---|---|---|---|
| Q3 FY2026 | Wed, Nov 4, 2026 | after close | 35 | 8-K |
| Q2 FY2026 | Mon, Jul 27, 2026 | after close | 27 | 8-K |
| Q1 FY2026 | Tue, Apr 28, 2026 | after close | 28 | 8-K |
| Q4 FY2025 | Thu, Feb 26, 2026 | after close | 57 | 8-K |
| Q3 FY2025 | Wed, Oct 29, 2025 | after close | 29 | 8-K |
| Q2 FY2025 | Thu, Jul 31, 2025 | after close | 31 | 8-K |
| Q1 FY2025 | Wed, Apr 30, 2025 | after close | 30 | 8-K |
| Q4 FY2024 | Thu, Feb 27, 2025 | after close | 58 | 8-K |
What they guided beta
| Q3 FY2026 | "Early data is expected to be presented in late 2026 or early 2027." exhibit |
| Q3 FY2026 | "We expect to report initial safety, tolerability, pharmacokinetic and immune data for both studies in the first half of 2027." exhibit |
| Q3 FY2026 | "Licensing, collaboration and other revenue for the third quarter of 2026 increased to $6.6 million from $1.8 million for the 2025 quarter, primarily driven by $5.8 million of royalty revenue from Lilly, partially offset by lower contract manufacturers’ commercial milestone revenue recognized by EirGen." exhibit |
| Q3 FY2026 | "Lower BARDA revenue in the third quarter of 2026 of $7.5 million compared with $8.2" exhibit |
| Q2 FY2026 | "We expect to report initial safety, tolerability, pharmacokinetic and immune data in the first half of 2027." exhibit |
| Q2 FY2026 | "In connection with the amendment, OPKO received an initial tranche of Series A-2 Preferred Shares and expects to close on the second equity issuance of Series A-2 Preferred Shares in the third quarter of 2026." exhibit |
| Q2 FY2026 | "higher revenue from the transfer of intellectual property and other, partially offset by lower revenue from services following the September 2025 sale of our oncology assets to Labcorp." exhibit |
| Q2 FY2026 | "Financial Guidance The table below contains financial guidance for the 2026 third quarter and full year financial guidance (in millions):" exhibit |
| Q2 FY2026 | "Conference Call and Webcast Information OPKO’s senior management will provide a business update, discuss second quarter financial results, provide financial guidance and answer questions during a conference call and live audio webcast today beginning at 4:30 p.m. ET." exhibit |
Get this as JSON
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/OPK
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/OPK
Put this date on your page
A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.
Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.
HTML
<a href="https://veritasdata.dev/company/OPK/"><img src="https://veritasdata.dev/embed/OPK.svg" alt="OPK earnings date" width="240" height="56"></a>
Markdown
[](https://veritasdata.dev/company/OPK/)
Script
<script async src="https://veritasdata.dev/embed/OPK.js"></script>
Get a free key: 100 calls, every company
Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.
curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/OPK"
Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.